Publications by authors named "Peter Alping"

Claim this Profile
C
Completeness and generalizability of the Swedish MS register.
Peter Alping, Thomas Frisell, Anna He, Jan Hillert, Katharina Fink

Eur J Epidemiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis.
Fredrik Sandesjö, Peter Alping, Katharina Fink, Ronny Wickström, Fredrik Piehl

Mult Scler J Exp Transl Clin· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
Fredrik Piehl, Peter Alping, Suvi Virtanen, Simon Englund, Joachim Burman

Ann Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
Yihan Hu, Thomas Frisell, Peter Alping, Huan Song, Yudi Pawitan

Ann Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell

Ann Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying therapies in multiple sclerosis: A focused review of rituximab.
Peter Alping

Basic Clin Pharmacol Toxicol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study.
Katharina Fink, Agnes Gorczyca, Peter Alping, Simon Englund, Susan Farmand

Mult Scler· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis.
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, Fredrik Piehl

Neurology· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn

Ann Neurol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn

JAMA Neurol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.
Peter Alping, Fredrik Piehl, Annette Langer-Gould, Thomas Frisell,

Epidemiology· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Peter Alping, Thomas Frisell, Anders Svenningsson, Fredrik Piehl

Ann Neurol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck

Neurology· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer

Ann Neurol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis